{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:01:43Z","timestamp":1785416503482,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Suven Life Sciences Limited, India"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.ejphar.2011.06.032","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T00:46:06Z","timestamp":1309913166000},"page":"155-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Antinociceptive activity of \u03b14\u03b22* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain"],"prefix":"10.1016","volume":"668","author":[{"given":"Ramakrishna","family":"Nirogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Jayarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renny","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanalakshmi","family":"Shanmuganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Abdul","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Kumar","family":"Royapalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Goura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2011.06.032_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lfs.2006.08.011","article-title":"Analgesic action of nicotine on tibial nerve transection (TNT)-induced mechanical allodynia through enhancement of the glycinergic inhibitory system in spinal cord","volume":"80","author":"Abdin","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0010","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1468-1331.2006.01511.x","article-title":"EFNS guidelines on pharmacological treatment of neuropathic pain","volume":"13","author":"Attal","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0161-813X(03)00043-3","article-title":"A new animal model of vincristine induced nociceptive peripheral neuropathy","volume":"24","author":"Authier","year":"2003","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.279.5347.77","article-title":"Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors","volume":"279","author":"Bannon","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0025","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0006-8993(98)00596-4","article-title":"ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain","volume":"801","author":"Bannon","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0030","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0022-3565(24)37423-3","article-title":"ABT-594 [(R)-5-2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization","volume":"285","author":"Bannon","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0035","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/j.1399-6576.2005.00814.x","article-title":"Peri-operative ketamine for acute postoperative pain: a quantitative and qualitative systematic review (Cochrane review)","volume":"49","author":"Bell","year":"2005","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","article-title":"A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man","volume":"33","author":"Bennett","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0045","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/jpet.108.139410","article-title":"Specific antinociceptive activity of Cholest-4-en-3-one, Oxime (TRO19622) in experimental models of painful diabetic and chemotherapy induced neuropathy","volume":"326","author":"Bordet","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1179\/joc.2002.14.2.214","article-title":"Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study","volume":"14","author":"Bosnjak","year":"2002","journal-title":"J. Chemother."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/mi.4.5.8","article-title":"Neuronal nicotinic receptor subtypes: defining therapeutic targets","volume":"4","author":"Buccafusco","year":"2004","journal-title":"Mol. Interv."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0060","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/1568026043451438","article-title":"Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity","volume":"4","author":"Bunnelle","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1744-8069-3-5","article-title":"Mechanically -evoked C-fiber activity in painful alcohol and AIDS therapy neuropathy in the rat","volume":"3","author":"Chen","year":"2007","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0070","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.2174\/1381612054865082","article-title":"NMDA antagonists and neuropathic pains-multiple drug targets and multiple uses","volume":"11","author":"Chizh","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0075","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0022-3565(24)37871-1","article-title":"Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (\u00b1)-epibatidine in rats","volume":"28","author":"Curzon","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0080","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1124\/jpet.106.112649","article-title":"Genetic approaches identify differential roles for \u03b14\u03b22 nicotinic receptors in acute models of antinoception in Mice","volume":"321","author":"Damaj","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1213\/01.ANE.0000131967.69309.4F","article-title":"Differential analgesic sensitivity of two distinct neuropathic pain models","volume":"99","author":"Decosterd","year":"2004","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0090","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0006-8993(02)03828-3","article-title":"Mechanical hyperalgesia in rat models of systemic and local hyperalgycemia","volume":"960","author":"Dobretsov","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pbb.2004.10.016","article-title":"Comparison of five different rat models of peripheral nerve injury","volume":"80","author":"Dowdall","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0304-3959(98)00239-5","article-title":"Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat","volume":"80","author":"Field","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0105","first-page":"341","article-title":"Anangesics and antipretics","volume":"2","author":"Frederics","year":"2000"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pain.2010.01.007","article-title":"Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain","volume":"149","author":"Gao","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0115","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1021\/jm970377o","article-title":"Neuronal nicotinic acetylcholine receptors as targets for drug discovery","volume":"40","author":"Holladay","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0120","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/jm9706224","article-title":"Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors","volume":"41","author":"Holladay","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neulet.2008.02.051","article-title":"The impact of bodyweight and body condition on behavioral testing for painful diabetic neuropathy in the streptozotocin rat model","volume":"436","author":"Hoybergs","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0130","first-page":"241","article-title":"A guide to drug evaluation for chronic pain","volume":"5","author":"Jain","year":"2000","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0135","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1021\/jm040219e","article-title":"Neuronal nicotinic acetylcholine receptors: structure revelations, target identifications, and therapeutic inspirations","volume":"48","author":"Jensen","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0140","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.bcp.2007.08.010","article-title":"A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo [3.2.0]-heptane \u03b14\u03b22 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models","volume":"74","author":"Ji","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0145","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1021\/jm070755h","article-title":"Synthesis and structure-activity relationship studies of 3,6-diazabicyclo [3.2.0] heptanes as novel \u03b14\u03b22 nicotinic acetylcholine receptor selective agonists","volume":"50","author":"Ji","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpain.2007.09.004","article-title":"Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain","volume":"9","author":"Joshi","year":"2008","journal-title":"J. Pain"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0155","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1021\/jm061023c","article-title":"Neuropathic pain: molecular complexity underlies continuing unmet medical need","volume":"50","author":"Kennedy","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0304-3959(00)00233-5","article-title":"Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain","volume":"86","author":"Kesingland","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0165","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0022-3565(24)29532-X","article-title":"A-85380 and epibatidine each interact with disparate spinal nicotinic receptor subtypes to achieve analgesia and nociception","volume":"297","author":"Khan","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0170","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0304-3959(92)90041-9","article-title":"An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat","volume":"50","author":"Kim","year":"1992","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0175","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF02450318","article-title":"Comparison of three rodent neuropathic pain models","volume":"113","author":"Kim","year":"1997","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejphar.2004.12.034","article-title":"ABT-594 (a nicotinic acetylcholine agonist): antiallodynia in a rat chemotherapy-induced pain model","volume":"509","author":"Lynch","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrd1929","article-title":"COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs","volume":"5","author":"Mitchell","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0304-3959(01)00294-9","article-title":"Vincristine-induced allodynia in the rat","volume":"93","author":"Nozaki-Taguchi","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0014-2999(93)90043-H","article-title":"Epibatidine is a nicotinic analgesic","volume":"250","author":"Qian","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-007-0758-3","article-title":"In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2\/3 receptor agonist LY404039 in animal models of psychiatric disorders","volume":"193","author":"Rorick-Kehn","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0205","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2009.06.013","article-title":"A randomized, double blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain","volume":"146","author":"Rowbotham","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0210","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0006-8993(00)02472-0","article-title":"Spinal mechanisms underlying A-85380-induced effects on acute thermal pain","volume":"872","author":"Rueter","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0215","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/s0304-3959(02)00455-4","article-title":"Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain","volume":"103","author":"Rueter","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0220","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1527-3458.2006.00100.x","article-title":"A-85380: a pharmacological probe for the preclinical and clinical investigation of the \u03b14\u03b22 neuronal nicotinic acetylcholine receptor","volume":"12","author":"Rueter","year":"2006","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0225","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0304-3959(90)91074-S","article-title":"A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury","volume":"43","author":"Seltzer","year":"1990","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0230","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0028-3908(96)84644-2","article-title":"A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity \u03b14\u03b22 nicotinic acetylcholine receptor ligand","volume":"35","author":"Sullivan","year":"1996","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2011.06.032_bb0235","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1124\/jpet.106.118604","article-title":"Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo [2.2.1] heptane (WAY-132983) in in vitro and in vivo models of chronic pain","volume":"322","author":"Sullivan","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0240","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s11940-996-0006-x","article-title":"Neurologic complications of cancer therapy","volume":"1","author":"Uhm","year":"1999","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.ejphar.2011.06.032_bb0245","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.neuroscience.2006.09.044","article-title":"Chemotherpy evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit","volume":"144","author":"Xiao","year":"2007","journal-title":"Neuroscience"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911007394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911007394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:05:38Z","timestamp":1785413138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299911007394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":49,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0014299911007394"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.06.032","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antinociceptive activity of \u03b14\u03b22* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}